Related Experiment Video

Updated: Apr 18, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

[Association between apolipoprotein A1-75 bp gene polymorphisms and risk for dyslipidemia and coronary artery

Xuebiao Wei1, Yaowang Lin1, Xing Yang1

  • 1Graduate School, Southern Medical University, Guangzhou 510080, China.

Zhonghua Xin Xue Guan Bing Za Zhi
|January 27, 2015
PubMed

Insights

The apolipoprotein A1 (ApoA1)-75 bp gene polymorphism is associated with dyslipidemia and coronary artery disease (CAD). This genetic variation acts as an independent protective factor against developing CAD.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Lipid Metabolism

Background:

  • Dyslipidemia and coronary artery disease (CAD) are significant global health concerns.
  • Genetic factors play a crucial role in the pathogenesis of these conditions.
  • The apolipoprotein A1 (ApoA1) gene is a key regulator of lipid metabolism and has been implicated in cardiovascular risk.

Purpose of the Study:

  • To investigate the association between the apolipoprotein A1 (ApoA1)-75 bp gene polymorphism and the risk of dyslipidemia.
  • To determine the relationship between the ApoA1-75 bp gene polymorphism and the prevalence of coronary artery disease (CAD).
  • To identify ApoA1-75 bp gene polymorphism as a potential predictive marker for cardiovascular risk.

Main Methods:

  • A cohort of 723 patients admitted to Guangdong General Hospital between 2011 and 2013 were analyzed.
  • Patients were categorized into coronary artery disease (CAD) and non-CAD groups based on coronary angiography.
  • Lipid profiles, ApoA1-75 bp gene polymorphisms, and Gensini scores were assessed to determine correlations.

Main Results:

  • Patients with CAD exhibited significantly higher levels of triglycerides, LDL-C, and ApoB, and lower HDL-C compared to the non-CAD group.
  • The frequency of the A allele for the ApoA1-75 bp polymorphism was significantly lower in the CAD group.
  • ApoA1-75 bp gene polymorphism was significantly correlated with CAD, with the mutation identified as an independent protective factor (OR = 0.649, P = 0.021).

Conclusions:

  • The ApoA1-75 bp gene polymorphism is significantly associated with an altered risk profile for dyslipidemia.
  • This specific genetic variation in the ApoA1 gene is linked to a reduced risk of developing coronary artery disease (CAD).
  • ApoA1-75 bp gene polymorphism may serve as a valuable genetic marker for predicting cardiovascular disease risk.
Abstract

More Related Videos

Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

41.2K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.8K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.2K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
166